Mebias presented rat data showing its mu opioid drugs could become a weapon in the scramble to combat the opioid epidemic.

Scientists at Max Planck Florida have developed a tool that allows for precise genome editing of neurons.

In our EuroBiotech roundup this week, Lytix prepares for IPO, Roche advances Alzheimer’s asset and Antabio raises cash for antibiotic trial. 

In this week's EuroBiotech Report, Lilly and CureVac pen $1.8 billion mRNA pact, AstraZeneca reveals Brexit pain, uniQure switches drugs and more.

The study linked synthetic oral endocannabinoid-mimetic anabasum to a statistically significant drop on a skin disease scale.

People are turning down jobs at AstraZeneca because of uncertainty about their right to stay in the United Kingdom after Brexit.

Forge Therapeutics and Evotec have launched a discovery platform to develop novel antibiotics targeting metalloenzymes.

The TRK TKI achieved a median duration of response of 28.6 months, suggesting its effect may last longer than that of the incumbent.

The series B round equips the Stanford University spinout to expand trials of its CD47-targeted approach to dialing up phagocytosis of cancer cells.

A back-loaded deal with CureVac moves Lilly into an emerging field that seeks to use mRNA to guide immune attacks on tumors.